NKX2-1 and acute lymphoblastic leukemia: Based on our cohort, we were able to classify T-ALL patients based on their molecular subgroups into good risk (TLX1, NKX2-1, LMO1), intermediate risk (HOXA), and poor risk (LYL1/LMO2, HOXA13, TAL1/LMO, TLX3).